Anti-CD19 CAR-T for B cell non-Hodgkin lymphoma
- CD19 is a protein, expressed on the surface of almost all B cell leukemias and lymphomas.
Anti-CDX CAR-T for B cell non-Hodgkin lymphoma
- CDX is a protein, expressed on the surface of almost all B cell leukemias and lymphomas. CDX can be used as an alternative to CD19.
- Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cells). The two main categories of lymphomas are Hodgkin’s lymphoma (HL) and the non-Hodgkin lymphoma (NHL). About 90% of lymphomas are NHL. Also, about 4.3 million people had NHL and 231,400 died in 2015. In the United States, over 70,000 cases of NHL are diagnosed and 19,000 people died each year. CancerPeutics has a plan to treat B-cell NHL using anti-CD19 and anti-CDX CAR-T cell therapeutics.
HVEM targeted CAR-T for melanoma
- HVEM is a protein that highly expressed on the surface of almost all melanoma.
- Melanoma is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but rarely in the mouth, intestines, or eye. The primary cause of melanoma is ultraviolet light (UV) exposure. Melanoma is the most dangerous type of skin cancer. Globally, in 2012, it newly occurred in 232,000 people. In 2015, there were 3.1 million with active disease which resulted in 59,800 deaths. Australia and New Zealand have the highest rates of melanoma in the world.
Pipeline
